Anti-CD45RO antibody [UCH-L1] (ab23)
Key features and details
- Mouse monoclonal [UCH-L1] to CD45RO
- Suitable for: WB, IHC-P, Flow Cyt
- Reacts with: Human
- Isotype: IgG2a
Overview
-
Product name
Anti-CD45RO antibody [UCH-L1]
See all CD45RO primary antibodies -
Description
Mouse monoclonal [UCH-L1] to CD45RO -
Host species
Mouse -
Tested applications
Suitable for: WB, IHC-P, Flow Cytmore details -
Species reactivity
Reacts with: Human -
Immunogen
Tissue, cells or virus corresponding to CD45RO. Cultured T cells from an IL-2-dependent T-cell line (CA1) prepared from human peripheral blood activated with influenza virus.
-
Positive control
- IHC-P: Human tonsil tissue. WB: Human tonsil and thymus tissue lysate.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.02% Sodium azide
Constituent: 99.98% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
UCH-L1 -
Myeloma
P3-NS1/1-Ag4-1 -
Isotype
IgG2a -
Research areas
Associated products
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab23 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use a concentration of 5 µg/ml. Detects a band of approximately 180 kDa (predicted molecular weight: 131 kDa).
|
|
IHC-P | (3) |
Use at an assay dependent concentration.
|
Flow Cyt |
Use at an assay dependent concentration.
|
Notes |
---|
WB
Use a concentration of 5 µg/ml. Detects a band of approximately 180 kDa (predicted molecular weight: 131 kDa). |
IHC-P
Use at an assay dependent concentration. |
Flow Cyt
Use at an assay dependent concentration. |
Target
-
Function
Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity. -
Involvement in disease
Defects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain. -
Sequence similarities
Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
Contains 2 fibronectin type-III domains.
Contains 2 tyrosine-protein phosphatase domains. -
Domain
The first PTPase domain interacts with SKAP1. -
Post-translational
modificationsHeavily N- and O-glycosylated. -
Cellular localization
Membrane. Membrane raft. Colocalized with DPP4 in membrane rafts. - Information by UniProt
-
Database links
- Entrez Gene: 5788 Human
- Omim: 151460 Human
- SwissProt: P08575 Human
- Unigene: 654514 Human
-
Alternative names
- B220 antibody
- CD45 antibody
- cd45 antigen antibody
see all
Images
-
ab23 (1 µg/ml) staining CD45RO in human tonsil.
Sections were stained using an automated system (DAKO Autostainer Plus ), at room temperature: sections were rehydrated and antigen retrieved with the Dako 3 in 1 AR buffers citrate pH 6.1. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 minutes. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 minutes and detected with Dako envision flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with hematoxylin and coverslipped under DePeX. Please note that for manual staining we recommend to optimize the primary antibody concentration and incubation time (overnight incubation), and amplification may be required. -
All lanes : Anti-CD45RO antibody [UCH-L1] (ab23) at 5 µg/ml
Lane 1 : Human tonsil normal tissue lysate - total protein (ab29615)
Lane 2 : Human thymus tissue lysate - total protein (ab30146)
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Mouse IgG H&L (HRP) preadsorbed (ab97040) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 131 kDa
Observed band size: 180 kDa why is the actual band size different from the predicted?
Additional bands at: 120 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 8 minutes
CD45RO contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (21)
ab23 has been referenced in 21 publications.
- Rafat M et al. Bioengineered corneal tissue for minimally invasive vision restoration in advanced keratoconus in two clinical cohorts. Nat Biotechnol 41:70-81 (2023). PubMed: 35953672
- Yang X et al. Integrative immunogenomic analysis reveals transcriptional and immune-related differences in hepatocellular carcinoma patients with different disease-free survival. Am J Cancer Res 12:1752-1765 (2022). PubMed: 35530269
- Wu K et al. Accumulation of CD45RO+CD8+ T cells is a diagnostic and prognostic biomarker for clear cell renal cell carcinoma. Aging (Albany NY) 13:14304-14321 (2021). PubMed: 34016791
- Sudo T et al. Diversity and shared T-cell receptor repertoire analysis in esophageal squamous cell carcinoma. Oncol Lett 22:618 (2021). PubMed: 34257726
- He Y et al. Molecular predictors of response to pembrolizumab in thymic carcinoma. Cell Rep Med 2:100392 (2021). PubMed: 34622229